One third of the world’s population is impacted by dermatologic conditions inclusive of skin, nail and hair disorders. The emergence of biologic therapies for dermatologic conditions created a paradigm shift for these patients, especially those who have not responded well to topical treatments, phototherapy or small molecule drugs. Typically offered as a second or third-line therapy, biologics offer treatment options for patients often with the most severe or debilitating presentations of dermatologic conditions.
By targeting the underlying disease and inflammatory mechanism, biologics have an advantage over topics therapies. Additionally, their targeted impact on the immune system typically results in few adverse events. However, biologics are not without side effects. Allergic reactions and antibody formation and infections are seen. Less common but more alarming side effects can include malignancies, demyelinating disease and hepatitis.
In a recent white paper, “Biologics – The Key to Next Generation Dermatology R&D?” Novella Clinical experts explore the evolution of biologics within the dermatology landscape, with an emphasis on clinical trial considerations for sponsors developing biologic agents.
For more information on developing biologics to treat dermatologic conditions, contact our experts at Novella Clinical.